0000950170-24-027304.txt : 20240306 0000950170-24-027304.hdr.sgml : 20240306 20240306170615 ACCESSION NUMBER: 0000950170-24-027304 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240305 FILED AS OF DATE: 20240306 DATE AS OF CHANGE: 20240306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WINDSOR JAMES BRIAN CENTRAL INDEX KEY: 0001790933 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38130 FILM NUMBER: 24726898 MAIL ADDRESS: STREET 1: 2600 VIA FORTUNA, SUITE 360 CITY: AUSTIN STATE: TX ZIP: 78746 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AILERON THERAPEUTICS INC CENTRAL INDEX KEY: 0001420565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 134196017 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 738 MAIN STREET STREET 2: UNIT 398 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-995-0900 MAIL ADDRESS: STREET 1: 738 MAIN STREET STREET 2: UNIT 398 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 ownership.xml 4 X0508 4 2024-03-05 0001420565 AILERON THERAPEUTICS INC ALRN 0001790933 WINDSOR JAMES BRIAN C/O AILERON THERAPEUTICS, INC. 738 MAIN STREET #398 WALTHAM MA 02451 false true false false President and COO false Common Stock 2024-03-05 4 M false 2000 A 7122 D Common Stock 225 I By son Series X Non-Voting Convertible Preferred 2024-03-05 4 M false 2 D Common Stock 2000 0 D On March 5, 2024, the Issuer's outstanding Series X Non-Voting Convertible Preferred Stock, par value $0.001 per share ("Series X Preferred Stock") automatically converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"), subject to certain beneficial ownership limitations. By operation of the certificate of designation for the Series X Preferred Stock, each share of Series X Preferred Stock was converted into 1,000 shares of Common Stock for no consideration. The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. /s/ James Brian Windsor 2024-03-06